Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Takeda’s study of subcutaneous vedolizumab meets primary goal

CD-vs-UC
Vedolizumab IV has approvals to treat moderately to severely active Crohn’s disease and ulcerative colitis in certain patients. Credit: RicHard-59.